DMAC DiaMedica Therapeutics Inc
Price (delayed)
$3.96
Market cap
$169.71M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.6
Enterprise value
$167.02M
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments to improve the lives of patients with neurological and chronic kidney diseases.
Highlights
DMAC's debt is down by 15% year-on-year and by 7% since the previous quarter
The quick ratio has plunged by 57% YoY and by 30% from the previous quarter
The net income has contracted by 26% YoY and by 13% from the previous quarter
Key stats
What are the main financial stats of DMAC
Market
Valuations
Earnings
Shares outstanding
42.86M
Market cap
$169.71M
Enterprise value
$167.02M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.16
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$26.68M
Net income
-$24.44M
EBIT
-$24.41M
EBITDA
-$24.3M
Free cash flow
-$22.1M
Per share
Balance sheet
Liquidity
EPS
-$0.6
EPS diluted
-$0.6
Free cash flow per share
-$0.55
Book value per share
$0.95
Revenue per share
$0
TBVPS
$1.15
Total assets
$46.35M
Total liabilities
$5.63M
Debt
$340,000
Equity
$40.72M
Working capital
$39.22M
Debt to equity
0.01
Current ratio
8.28
Quick ratio
8.23
Net debt/EBITDA
0.11
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-47.7%
Return on equity
-51.9%
Return on invested capital
-58.2%
Return on capital employed
-59.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DMAC stock price
How has the DiaMedica Therapeutics stock price performed over time
Intraday
5.6%
1 week
-2.94%
1 month
-39.36%
1 year
45.05%
YTD
-27.07%
QTD
4.49%
Financial performance
How have DiaMedica Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$26.68M
Net income
-$24.44M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 26% YoY and by 13% from the previous quarter
The operating income has contracted by 25% YoY and by 11% from the previous quarter
Growth
What is DiaMedica Therapeutics's growth rate over time
Valuation
What is DiaMedica Therapeutics stock price valuation
P/E
N/A
P/B
4.16
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 7% QoQ
The stock's price to book (P/B) is 23% more than its 5-year quarterly average of 3.2 and 13% more than its last 4 quarters average of 3.5
DiaMedica Therapeutics's equity has decreased by 20% YoY and by 15% from the previous quarter
Efficiency
How efficient is DiaMedica Therapeutics business performance
DiaMedica Therapeutics's return on invested capital has decreased by 37% YoY and by 19% QoQ
DiaMedica Therapeutics's return on equity has decreased by 29% YoY and by 20% QoQ
The return on assets has declined by 26% year-on-year and by 17% since the previous quarter
Dividends
What is DMAC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DMAC.
Financial health
How did DiaMedica Therapeutics financials performed over time
DiaMedica Therapeutics's total liabilities has soared by 81% YoY and by 23% from the previous quarter
The quick ratio has plunged by 57% YoY and by 30% from the previous quarter
DMAC's debt is 99% smaller than its equity
DiaMedica Therapeutics's equity has decreased by 20% YoY and by 15% from the previous quarter
DMAC's debt is down by 15% year-on-year and by 7% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.